Novo Nordisk is currently plowing billions of dollars into new facilities to satiate the rip-roaring demand for its GLP-1 cocktail Wegovy. Yet, a sizable supply-demand gap persists, prompting the pharma giant to flag the possibility of "supply disruptions" in the near term. To wit, Novo Nordisk has now announced via a supply update that it has resumed the shipments of 1.7 mg dose strength Wegovy GLP-1 cocktail in the US following a "short-term stock-out." Bear in mind that 1.7 and 2.4 mg dose strengths are primarily geared toward weight loss maintenance. However, the company chose to flag the potential for […]
Read full article at https://wccftech.com/novo-nordisk-nvo-flags-supply-disruptions-for-its-wegovy-glp-1-weight-loss-drug-amid-soaring-demand-as-the-fda-quantifies-small-suicide-risk/
WccftechContinue reading/original-link]